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TCF4 is involved in neurodevelopment, and intergenic and intronic variants in or close to the TCF4 gene have been associated
with susceptibility to schizophrenia. However, the functional role of TCF4 at the level of gene expression and relationship to
severityofcorepsychoticphenotypesarenotknown.TCF4mRNAexpressionlevelinperipheralbloodwasdeterminedinalarge
sample of patients with psychosis spectrum disorders (n¼596) and healthy controls (n¼385). The previously identiﬁed TCF4
risk variants (rs12966547 (G), rs9960767 (C), rs4309482 (A), rs2958182 (T) and rs17512836 (C)) were tested for association with
characteristic psychosis phenotypes, including neurocognitive traits, psychotic symptoms and structural magnetic resonance
imaging brain morphometric measures, using a linear regression model. Further, we explored the association of additional 59
single nucleotide polymorphisms (SNPs) covering the TCF4 gene to these phenotypes. The rs12966547 and rs4309482 risk
variants were associated with poorer verbal ﬂuency in the total sample. There were signiﬁcant associations of other TCF4 SNPs
withnegative symptoms,verballearning,executivefunctioningandage atonsetinpsychoticpatientsandbrain abnormalitiesin
total sample. The TCF4 mRNA expression level was signiﬁcantly increased in psychosis patients compared with controls and
positively correlated with positive- and negative-symptom levels. The increase in TCF4 mRNA expression level in psychosis
patients and the association of TCF4 SNPs with core psychotic phenotypes across clinical, cognitive and brain morphological
domains support that common TCF4 variants are involved in psychosis pathology, probably related to abnormal
neurodevelopment.
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Introduction
Schizophrenia and bipolar disorder are characterized by
psychotic symptoms, mood dysregulation and cognitive
dysfunction, and are regarded as complex genetic disorders
with mainly unknown underlying pathophysiology. Despite the
high heritability, the genetic susceptibility factors are only
partly understood. Large genome-wide association studies
(GWAS) have provided the opportunity to identify new genes
and genetic variation in new pathways.
1 Using appropriate
sample sizes, GWAS have identiﬁed several disease-asso-
ciated gene variants,
2–4 and in schizophrenia, these studies
indicate the presence of neurodevelopmental and immune-
related mechanisms.
4,5
One of the ﬁndings in schizophrenia is association to the
gene transcription factor 4 (TCF4), located on chromosome
18q21,codingfora basichelix–loop–helix transcriptionfactor.
First, Stefansson et al. (2009)
4 combined data from several
GWAS and reported seven single nucleotide polymorphisms
(SNPs) associated with schizophrenia at a genome-wide
level, including rs9960767 located in an intron of TCF4
(P¼4.1 10
 9). A study of Han Chinese patients replicated
this association through another SNP (rs2958182, in high
linkage disequilibrium (LD) with rs9960767).
6 Rs4309482,
situated intergenically downstream of TCF4 and upstream of
CCDC68, was reported in another large GWAS.
7 Finally,
in recent mega-analyses, two new TCF4 SNPs (rs17512836
(intron 3 of TCF4) and rs12966547 (in high LD with
rs4309482)) were identiﬁed and further supported TCF4 as
a disease gene for schizophrenia.
5 Interestingly, TCF4 has
also been associated with bipolar disorder,
8 which is in line
with the growing evidence supporting overlapping genetic
factors in schizophrenia and bipolar disorders
9,10 and
corresponding to the overlapping clinical and neurocognitive
features.
11 It is possible that TCF4 risk loci confer risk for
psychosis-related phenotypes across diagnostic boundaries.
TCF4 variations have been shown to be responsible
for Pitt–Hopkins syndrome characterized by severe mental
retardation, developmental delay, microcephaly, hyper-
ventilation episodes and characteristic dysmorphisms
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12,13 Haploinsufﬁciency caused by deletions
and nonsense mutations is the presumed molecular mecha-
nism, but missense mutations are also seen.
12 Thus, genetic
variation in TCF4 may affect cognition and several neuro-
psychiatric phenotypes in both psychiatric patients and
controls.
13
Cell and animal studies have indicated an important role of
TCF4 in neuronal development. It is highly expressed in the
embryonic central nervous system and schlerotomal compo-
nentofthesomitesandtheadultbrain
14andseveredisruption
in pontine nuclei development has been reported in TCF4
 / 
mice.
15 In addition, cognitive impairments and deﬁcits in
pre-pulse inhibition were found in mice overexpressing TCF4
intheforebrain.
16ThesestudiesindicatethatTCF4mayaffect
a range of brain-related phenotypes, but with regard to
psychosis, TCF4 has mainly been investigated in relation to
case-control status.
The neurodevelopmental hypothesis for schizophrenia is
supported by the observations of increased occurrence
of obstetric complications, reduced premorbid function in
children who later develop schizophrenia, cognitive dysfunc-
tion, positive and negative symptoms and reduced cortical
thickness and enlarged ventricles in the early phases of the
disease.
17–19 It is possible that common variants in genes
controlling neurodevelopment, such as TCF4, confer risk
for phenotypes related to neurodevelopmental aspects of
psychosis.
The object of the current study was to further elucidate the
roleof TCF4 in psychosispathology, by testing the hypothesis
that TCF4 variants are associated with psychosis phenotypes
relatedtoabnormalneurodevelopment.WedeterminedTCF4
mRNA expression level in patients with psychotic disorders
and controls. Next, we tested whether previously identiﬁed
schizophrenia risk variants (rs12966547, rs2958182,
rs9960767, rs4309482 and rs17512836)
4–7 in TCF4 were
associatedwithneurodevelopmental phenotypesofpsychotic
disorders (early age at onset, positive and negative symp-
toms, cognitive dysfunction and brain magnetic resonance
imaging (MRI) morphometric measures) independent of
diagnostic boundaries using a large well-described sample
of patients with schizophrenia and bipolar disorder and
healthy controls. Further, we aimed to explore any speciﬁc
association with the schizophrenia diagnostic group. Finally,
we did an exploratory association analysis with other TCF4
variants.
Methods and materials
Sample. The participants are part of a larger Norwegian
study sample (Thematically Organized Psychosis (TOP)
Study), which is a collaborative study involving the
University of Oslo and all the Hospitals in the Oslo region,
funded by the University, Regional Health Authorities and the
Research Council of Norway.
A total of 596 patients with psychotic disorders or affective
psychosisaccordingtoDSM-IVand385healthycontrolswere
included. The patients were divided into three groups: (1)
schizophrenia spectrum disorders, referred to as schizophre-
nia in the following: encompassing schizophrenia (n¼225),
schizoaffective disorder (n¼23) and schizophreniform dis-
order (n¼52), (2) bipolar spectrum disorder, referred to
as bipolar disorder in the following: encompassing bipolar
disorder type 1 (n¼131), bipolar disorder type 2 (n¼60),
bipolar disorder not otherwise speciﬁed (n¼13) and major
depressive disorder with psychosis (n¼19) and (3) psychosis
classiﬁed as ‘other psychosis’, that is, non-schizophrenia or
bipolar disorder (n¼73). Main inclusion criteria in addition to
the mentioned DSM-IV disorders were age between 18 and
65 years, absence of mental retardation and no history of
major brain trauma.
The group of healthy controls (n¼385) was from the same
catchment area as the patient group and randomly selected
from national statistical records (www.ssb.no). The healthy
control sample was evaluated with a clinical interview about
severe mental disorder symptoms and the Primary Care
Evaluation of Mental Disorders (PRIME-MD).
20 The subjects
were excluded if they or any of their close relatives had a
lifetime history of a severe psychiatric disorder (schizophre-
nia, bipolar disorder or major depression), if they had an
unstable medical condition known to interfere with brain
function, or substance abuse or dependency in the past
3 months. A detailed description of the sample has been
reported elsewhere.
21 Demographic and clinical data are
presented in Table 1.
In the described sample, a total of 895 participants had
both neurocognitive and genotype data, 542 had mRNA data
and genotype data, 480 had both brain imaging and genotype
data and a total of 717 had both mRNA and clinical data.
Furthermore, a total of 300 patients with schizophrenia
had clinical data and genotype data. For details, see Supple-
mentary Tables S1 and S2 online.
The study was approved by The Norwegian Scientiﬁc-
Ethical Committees and the Norwegian Data Protection
Agency, and the biobank was approved by the Health
Authorities. Written informed consent was given from all
participants before inclusion.
Clinical characterization. Clinical assessment was carried
out by trained physicians and clinical psychologists.
A standardized protocol of operational instruments was
used.
22 Diagnosis was based on the Structured Clinical
Interview for DSM-IV Axis I disorders (SCID-I).
23 Diagnostic
reliability was found satisfactory, with overall agreement
for DSM-IV diagnostic categories of 82% with k¼0.77
(95% conﬁdence interval: 0.60–0.94).
22 In addition,
information from follow-up visits was used to secure correct
diagnoses. In order to speciﬁcally address core psychotic
features, the following assessments were used: Current
positive and negative psychiatric symptoms were assessed
using the Positive and Negative Syndrome Scale (PANSS).
24
Psychosocial functioning in patients was assessed with the
Global Assessment of Functioning scale, split version.
25 Age
at onset was obtained from interview and/or hospital records.
For the current analysis, phenotypes related to neuro-
development (age at onset and positive and negative
symptoms (PANSS positive and negative sum-score)) were
selected.
17 All subjects reported their alcohol and drug intake
in the past 2 weeks before the interview.
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Translational PsychiatryNeuropsychological testing. All participants were tested
with a clinically relevant neuropsychological battery. For the
current analysis, cognitive tests that have revealed cognitive
dysfunction in schizophrenia and bipolar disorder were
selected.
11 The test battery included the following tests:
general cognitive function measured using the Wechsler
Abbreviated Scale of Intelligence (WASI).
26 Mental speed
was evaluated by the Digit Symbol Coding Test (WAIS-III).
27
Executive function was evaluated by the Inhibition and
Inhibition/Switching on Color-Word Interference Test,
and by Verbal Fluency Letter, Verbal Fluency Category and
Category Switching from the Verbal Fluency Test (Delis
Kaplan Executive Function System (D-KEFS)).
28 Verbal
memory was measured by the total learning score (trials
A1-5) from the California Verbal Learning Test- Second
edition (CVLT-II).
29 Low scores equal poorer performance for
all tests apart from the Color-Word Interference Test.
MR image acquisition and processing. A subsample of
480 participants underwent MRI scanning on the same 1.5T.
scanner (Siemens Magnetom Sonata scanner, Siemens
Medical Solutions, Erlangen, Germany) equipped with a
standard head coil at the Oslo University Hospital, Oslo,
Norway between 2003 and 2009.
30 After a conventional
3-plane localizer, two sagittal T1-weighted magnetization-
prepared rapid gradient echo volumes were acquired with the
Siemens tﬂ3d1_ns pulse sequence (TE¼3.93ms, TR¼
2730ms, TI¼1000ms, ﬂip angle¼71; FOV¼24cm, voxel
size¼1.33 0.94 1mm
3, number of partitions¼160).
Acquisition parameters were optimized for increased gray/
white matter image contrast. All brain scans were read by a
specialist in neuroradiology and were found to be free from
organic brain pathology (for example, tumors, bleeding,
infarcts and obstructive hydrocephalus).
The image ﬁles in DICOM format were transferred to a
Linux workstation for morphometric analysis. Images were
corrected for non-linear warping caused by gradient coil non-
linearities, using tools developed through the Morphometry
Biomedical Informatics Research Network,
31 and the two
T1-weighted images were rigid body registered to each other
(motion corrected). The FreeSurfer 3.0.2 software package
(http://surfer.nmr.mgh.harvard.edu) was used to obtain mea-
sures of subcortical volumes
32 and cortical area and thick-
ness.
33,34 Summary measures were generated and used as
structuralphenotypes.
35Formoredetails,seeSupplementary
Information online.
We included seven morphometric summation measures
35
shown to be abnormal in schizophrenia and bipolar dis-
orders:
30 frontal cortical area and thickness, temporal cortical
area and thickness, hippocampal volume, cerebellar volume
and total ventricular volume (comprising the lateral and
inferior lateral, third and fourth ventricle). Based on the ﬁnding
of microcephaly in patients with Pitt–Hopkins syndrome, we
also investigated total brain volume.
Genotyping and SNP selection. The sample was geno-
typed at Expression Analysis (Durham, NC, USA) using the
Affymetrix Genome-Wide Human SNP Array 6.0. (Affymetrix,
Santa Clara, CA, USA). Quality control was performed
using PLINK.
36 Details about genotyping and quality control
procedures are provided in supplementary information.
This resulted in a sample of 1377 individuals with suitable
genotype data available; of the 909,622 markers on the
array, 525,117 autosomal markers remained. The total
genotyping rate in remaining individuals was 0.993. We
extracted SNPs from the TCF4 gene region based on UCSC
coordinates± 20kb kb (chr 18, 52869562-53323185 bp
(hg19)) leaving a total of 59 SNPs (see Supplementary Table
S3 online). Five additional SNPs in or near the TCF4 gene
were selected because of association with schizophrenia
(rs12966547, rs2958182, rs9960767, rs4309482 and
rs17512836).
4–7 They were imputed by IMPUTE2
37 using
1000 genomes CEU sample as reference. LD blocks are
deﬁned by conﬁdence bounds on the normalized measure
of allelic association (D0)
38 (see Supplementary Figure S1
online).
Table 1 Demographics and clinical characteristics
a
Schizophrenia (n¼300) Bipolar disorder (n¼223) Other psychoses (n¼73) Healthy controls (n¼385)
Demographics
Age, years
b 32.6 (9.7) 36.0 (12.1) 33.0 (10.3) 34.6 (10.0)
Sex, n (% male) 161 (53.7) 85 (38.1) 47 (64.4) 197 (51.2)
Age at onset, years
c 27.2 (8.6) 28.3 (11.1) 26.1 (14.6) —
Symptom ratings
PANSS total score 64.2 (16.9) 46.3 (10.7) 55.8 (14.8) —
GAF symptom 41.3 (11.3) 57.0 (11.7) 48.5 (13.6) —
GAF function 42.5 (10.3) 54.6 (12.2) 50.4 (14.1) —
Medication N (%) N (%) N (%)
Antipsychotic 268 (89.3) 113 (50.6) 54 (74.0) —
Lithium 7 (2.3) 34 (15.2) 0 (0) —
Anticonvulsiva 60 (20.0) 98 (44.0) 8 (11.0) —
Antidepressants 89 (29.7) 84 (37.6) 26 (35.6) —
Sedatives 28 (12.4) 34 (11.3) 16 (21.9) —
Abbreviations: GAF, Global Assessment of Functioning; PANSS, Positive and Negative Syndrome Scale.
aMean and standard deviation are reported unless otherwise speciﬁed.
bAge was deﬁned asageat phenotype assessments.
cAge atonset was deﬁned as age atﬁrst
contact with the mental health service owing to a primary symptom.
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the Tempus 12-Port RNA Isolation kit (Applied Biosystems;
Ambion, Austin, TX, USA) and quantiﬁed using the ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA).
Quantitative real-time RT-PCR was performed by using the
ABI Prism 7900 HT sequence detection system (Applied
Biosystems, Foster City, CA, USA). RNA (1mg) was reverse-
transcribed using a high-capacity cDNA RT kit (Applied
Biosystems), and quantitative RT-PCR was performed using
TaqMan Gene Expression Master Mix (Applied Biosystems).
The Assays-on-Demand products purchased from Applied
Biosystems contained Taqman minor groove binder probes
(6-FAM dye-labeled) combined with the primers for the genes
of interest: TCF4 (Hs00162613_m1). An Assay-on-Demand
product for eukaryotic ACTB (ACTB: Hs99999903_m1) was
used as endogenous control. Details about RNA quantiﬁcation
procedure are provided in supplementary information online.
Statistical analysis. Potential differences in TCF4 mRNA
level between the diagnostic groups and control group were
analyzed using an analysis of covariance in the PASW software
package for Windows, version 18.0. (PASW, Chicago, IL).
TCF4 mRNA level was entered as the dependent variable,
diagnostic group as the independent variable. Age was
signiﬁcantly correlated with TCF4 mRNA level (Pearson
r¼0.14, Po0.005), and was entered as a covariate in the
analysis. Independent sample t-test showed no statistical effect
of gender on TCF4 mRNA level (t (714)¼0.99, P40.05). As
psychotropic medication may affect the TCF4 mRNA level,
a separate one-way analysis of variance was conducted to
explore the effect of medication. The patient sample was
divided into six non-overlapping groups based on their
prescription (1: Antipsychotics; 2: Lithium; 3: Anticonvulsiva;
4: Antidepressants; 5: Combinational treatment of more than
one type of psychotropic; 6: Unmedicated; see Supplementary
Table S4 online). Partial correlation (r) controlling for age was
used to investigate how positive and negative symptoms
related to TCF4 mRNA as a previously study had found a
correlation between delusions and TCF4 mRNA.
39
Associations between TCF4 SNPs and core psychotic
phenotypes were tested through the additive model of linear
regression in PLINK.
36 The whole sample was investigated for
associationtocognitivemeasures,MRIandmRNA.Additionally,
associationswithpsychosissymptomsandageatdiseaseonset
were investigated in the whole subset of patients. Each analysis
controlled for gender, age at sampling and diagnostic group
(‘schizophrenia’,‘bipolar’,‘otherpsychosis’orcontrol).Theeffect
in the schizophrenia group only, controlling for age and gender,
was also analyzed.
Our primary focus was the ﬁve SNPs (rs12966547,
rs9960767, rs2958182, rs4309482 and rs17512836) impli-
cated in schizophrenia. Firstly, we analyzed these SNPs with
general cognitive function, mental speed, executive function
and verbal memory, then PANSS and age at onset. Using the
same linear model, we investigated association to the eight
morphometric summation measures: frontal cortical area and
thickness, temporal cortical area and thickness, hippocampal
volume, cerebellar volume, total ventricular volume and total
brain volume.
Correction for multiple testing. A Bonferroni correction
method was used to correct for multiple testing across
independent variables after taking the correlation between
genotypes and phenotypes into account. LD blocks
determined by conﬁdence bounds on the normalized
measure of allelic association (D0) deﬁne number of
independent SNPs.
38 Several of the 19 phenotypes in the
current study are highly correlated (see correlation matrix,
Supplementary Table S5 online) and subdivision into
phenotype families is one method to account for this.
40 The
phenotype families in the current study are: (1) TCF4 mRNA,
(2) positive and negative symptoms, (3) cognitive tests
performance, and (4) brain morphological summary
measures. Owing to evidence that rs12966547, rs9960767,
rs2958182, rs4309482 and rs17512836 are associated with
schizophrenia and our a priori hypothesis for an association
between the risk SNPs and key phenotypes in psychosis,
Bonferroni correction for four independent SNPs (see
Supplementary Figure S1A online) and four independent
phenotype families were performed and signiﬁcance level
was set to Po0.0031 in these analyses. The 59 TCF4 SNPs
were tested for the same core psychosis phenotypes
mentioned above. The P-values for the SNP–phenotype
analyses were corrected for multiple testing with Bonferroni
correction for 14 independent SNPs (see Supplementary
Figure S1B online) and four independent phenotype families
and the signiﬁcance level was set to Po0.00089.
Results
TCF4 mRNA expression. We measured TCF4 mRNA
expression in the blood of patients with schizophrenia,
bipolar disorder, other psychoses and controls. There was
a signiﬁcant difference in TCF4 mRNA expression level
between the groups after correcting for age (F (3,711)¼8.23,
P¼2.2 10
 5), with a higher relative expression in patient
groups compared with controls (Figure 1). Post hoc Tukey
tests revealed signiﬁcantly higher relative mRNA level in all
individual patient groups in comparison to controls: schizo-
phrenia (2.22%, P¼9.0 10
 5), bipolar disorder (1.78%,
P¼0.005) and other psychoses (1.87%, P¼0.049) (see
Supplementary Table S6 online). No signiﬁcant difference
between the individual patient groups was observed (see
Supplementary Table S6 online). Medication status (see
Supplementary Table S4 online) was signiﬁcantly associated
with TCF4 mRNA level (F (5,499)¼2.7, P¼0.020). Post hoc
Tukey tests did not show any signiﬁcant mRNA differences
between the medication groups. Comparison of mRNA level
in all unmedicated patients (n¼74) and controls (n¼212)
revealed a trend of higher mRNA level in patients (t (284)¼
1.37, P¼0.17). Next, positive symptoms (r¼0.10, P¼
0.027) and negative symptoms (r¼0.13, P¼0.004) were
positively correlated with TCF4 mRNA level in total sample
and negative symptoms (r¼0.16, P¼0.016) in schizo-
phrenia sample (see Supplementary Table S7 online).
To investigate if the mRNA differences could be asso-
ciated with TCF4 gene variants, we tested SNPs previously
associated with schizophrenia: rs12966547, rs9960767,
rs2958182, rs4309482 and rs17512836 (the ‘schizophrenia
TCF4 and phenotypes in psychotic disorders
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the TCF4 gene, which we called the ‘exploratory analysis’.
Eachanalysiswasperformedintheentiresampleaswellasin
schizophrenia patients separately. Nominal signiﬁcant asso-
ciations between TCF4 SNP variants and TCF4 mRNA
expression levels were found (see Supplementary Table S7
online) but did not remain signiﬁcant after correcting for
multiple testing. No signiﬁcant eQTLs for TCF4 mRNA were
found in our data (data not shown).
TCF4 SNPs and clinical characteristics. Nominal signi-
ﬁcant results from the ‘schizophrenia SNP analysis’ are
presented in Table 2 and results remaining signiﬁcant
after correction for multiple testing from the ‘exploratory
analysis’ are presented in Table 3 and Figure 2. To investi-
gate if common TCF4 gene variants are associated with
sub-phenotypes of psychosis characteristic of abnormal
neurodevelopment, we tested PANSS positive and negative
sum scores and age at onset. In the ‘exploratory analysis’,
minor alleles of rs2958188 and major allele of rs9636107 in
each of their LD block were associated with younger age
at onset in the total patient sample, and minor alleles
of eleven SNPs (rs1261086, rs1261073, rs1261076,
rs1942265, rs7241077, rs1893431, rs4800988, rs1261134,
rs1788027, rs1660242 and rs1788014) from sequential
LD blocks were associated with less negative symptoms in
patients with schizophrenia (Table 3). There was no signi-
ﬁcant association with positive symptoms.
TCF4 SNPs and cognitive functions. We analyzed
whether the TCF4 SNPs were associated with cognitive dys-
function, another sub-phenotype of psychosis characteristic
of abnormal neurodevelopment. In the ‘schizophrenia SNP
analysis’, risk alleles of the tightly linked rs12966547 and
rs4309482 were associated with poorer performance on
Verbal Fluency in total sample after correction for multiple
testing (Table 2). In addition, risk alleles of rs12966547 and
s4309482 were associated with poorer verbal ﬂuency in
patients with schizophrenia and risk allele of rs2958182
was associated with better performance on Color-Word Inter-
ference test (inhibition) in patients with schizophrenia, but
these ﬁndings did not survive correction for multiple testing.
In the ‘exploratory analysis’, the minor alleles of rs1377243
and rs2958188 and major alleles of rs41396445 and
rs10871582 in two LD blocks were associated with poorer
performance on verbal memory (CVLT) in the schizophrenia
sample (Table 3).
TCF4 SNPs and structural brain MRI measures. We
tested if TCF4 SNPs were associated with MRI morpho-
metric summary measures in brain regions found to be
abnormal in psychosis. In the ‘schizophrenia SNP analysis’,
the risk alleles of rs12966547 and s4309482 were associated
with larger ventricular volumes and the risk allele of rs9960767
was associated with a larger hippocampus and smaller
Table 2 Results from the ‘schizophrenia SNPs’ and phenotypes analyses
SNP R
2 a
Localisation Minor
allele
MAF Risk
allele
Phenotype Sample N Beta
b SE P Corr
c
rs12966547 0.998 52752017 A 0.436 G
d Verbal ﬂuency
e All 890  1.75 0.55 0.0014 0.022
Verbal ﬂuency Schizophrenia 227  2.56 1.18 0.031 0.50
Ventricular volume All 480 1535 696 0.028 0.45
rs4309482 0.981 52750469 G 0.444 A
f Verbal ﬂuency All 890  1.81 0.55 0.0010 0.016
Verbal ﬂuency Schizophrenia 227  2.73 1.19 0.023 0.37
Ventricular volume All 480 1557 699 0.026 0.42
rs2958182 0.938 53149021 A 0.373 T
g Inhibition
h Schizophrenia 227  5.37 2.13 0.012 0.19
rs9960767 0.949 53155002 C 0.056 C
i Hippocampal volume All 480 207 102 0.043 0.69
Ventricular volume All 480  3811 1599 0.018 0.29
Abbreviations: MAF, minor allele frequency; N, number; SE, standard error; SNP, single nucleotide polymorphism.
aR
2 imputation score.
bBeta is estimated by increasing number of risk alleles.
cP-values in bold remained signiﬁcant after controlling for multiple testing across
independent genotypes and phenotype families.
dRipke et al.
eVerbal Fluency Letter from the Verbal Fluency Test (Delis Kaplan Executive Function System
(D-KEFS)).
fSteinberg et al.
gLi et al.
hInhibition from the Color-Word Interference Test (Delis Kaplan Executive Function System (D-KEFS)).
iStefansson et al.
Nominal signiﬁcant results (Po0.05) from the linear regression analysis of schizophrenia SNPs, correcting for diagnosis and gender.
Figure 1 Relative TCF4 mRNA expression between the diagnostic groups.
The ﬁgure shows signiﬁcantly lower TCF4 mRNA expression in healthy controls
(HC, n¼212) compared with ***schizophrenia (ScZ, n¼232, P¼8.6 10
 5),
**bipolar disorder (BD, n¼200, P¼0.005) and *other psychoses (OP, n¼73,
P¼0.049). Mean values with ± one standard error are presented.
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correction for multiple testing. The ‘exploratory analysis’
showed that the minor allele of three SNPs (rs41396445,
rs17514242 and rs10871582) in the same LD block were
associated with reduced temporal cortical area in total sample.
Out of these, minor alleles of two SNPs (rs17514242 and
rs10871582) were associated with reduced total brain volume
in total sample. The major alleles of three SNPs (rs682245,
rs12458118 and rs9951280) in the same LD block were
associated with decreased cerebellar volume in patients with
schizophrenia (Table 3).
Discussion
The main ﬁndings of the present study were upregulated
TCF4 expression level in all psychotic diagnostic groups and
that TCF4 risk variants associate with poorer verbal ﬂuency
in total sample. The exploratory analysis revealed that TCF4
variants associated with negative symptoms, cognitive
dysfunction and cerebellar volume in the schizophrenia
sample, age at onset in total patient sample and variants
correlating with temporal cortical area and brain volume in
total sample. This further implicates TCF4 in psychosis
pathophysiology, and indicates a speciﬁc role in the develop-
ment of clinical phenotypes related to aberrant neurodevelop-
ment. To our knowledge, this is the ﬁrst study on known TCF4
risk variants of schizophrenia and hitherto uncharacterized
variants targeting psychosis phenotypes at different levels,
including the peripheral TCF4 mRNA.
The analysis of known schizophrenia TCF4 risk variants
revealed that the two linked rs12966547 and rs4309482 are
associated with poorer executive function in the form of verbal
ﬂuency. Interestingly, reduced cognitive functioning has been
associated with enlarged ventricular volume,
41 corroborating
our ﬁnding that the same risk variants, rs12966547 and
rs4309482, were associated with larger ventricular volume
even though this did not survive correction for multiple testing.
Enlarged ventricular volume is one of the most consistent
ﬁndings in schizophrenia,
42 also found in bipolar disorder
43
and Pitt–Hopkins syndrome.
44 This indicates that these TCF4
risk SNPs might, at least partially, cause this common
subphenotype in schizophrenia.
41 The consistent pattern of
effect across different phenotypes strengthens the ﬁndings.
The pattern of associations in the non-schizophrenia
risk SNP analysis corroborates a relationship between
TCF4 and changes in brain morphology. Several SNPs in
one haploblock were associated with cerebellar volume,
temporal cortical area or brain volume. The Allan Brain
Atlas shows TCF4 expression in several parts of the brain,
most pronounced in hippocampus and cerebellum (http://
www.brain-map.org). This is consistent with a role of TCF4 in
early neurodevelopment
45 and embryogenesis
46 previously
shown in animal models as well as concordant with micro-
cephaly as a core characteristic of Pitt–Hopkins syndrome,
44
Table 3 Results of the ‘Explorative Analysis’ of TCF4 SNPs and phenotypes
LD
block
SNP Minor
allele
Phenotype Sample N Mean (s.d.)
a Mean (s.d.)
b Mean (s.d.)
c Effect
size
d
P Corr
e
1 rs1261086 C Negative symptoms Scz 282 13.51 (6.10) 15.51 (6.67) 16.94 (6.67)  0.21 0.00038 0.021
— rs1261073 G Negative symptoms Scz 281 13.39 (6.26) 15.06 (5.91) 17.26 (7.45)  0.23 0.00011 0.0062
2 rs1261076 C Negative symptoms Scz 282 13.69 (6.03) 15.22 (6.20) 17.91 (7.36)  0.24 0.000039 0.0022
2 rs1942265 G Negative symptoms Scz 282 13.23 (5.94) 14.86 (6.02) 16.85 (7.15)  0.20 0.00059 0.033
2 rs7241077 A Negative symptoms Scz 282 13.23 (5.94) 14.86 (6.02) 16.85 (7.15)  0.20 0.00059 0.033
2 rs1893431 A Negative symptoms Scz 282 13.47 (6.31) 15.02 (5.09) 17.26 (7.41)  0.22 0.00017 0.0095
2 rs4800988 A Negative symptoms Scz 282 13.23 (5.94) 14.86 (6.02) 16.85 (7.15)  0.20 0.00059 0.033
2 rs1261134 T Negative symptoms Scz 282 13.72 (6.30) 14.81 (5.85) 17.33 (7.37)  0.22 0.00011 0.0062
2 rs1788027 T Negative symptoms Scz 275 13.89 (6.14) 14.87 (6.14) 18.05 (7.22)  0.23 0.000077 0.0043
— rs1660242 T Negative symptoms Scz 281 14.05 (5.97) 14.85 (6.39) 17.17 (7.03)  0.21 0.00045 0.025
3 rs1788014 G Negative symptoms Scz 282 13.51 (6.10) 15.51 (6.67) 16.94 (6.67)  0.21 0.00038 0.021
5 rs1377243 T California verbal
learning
f
Scz 227 11.15 (2.84) 11.81 (2.58) 12.83 (2.59)  0.23 0.00044 0.025
6 rs2958188 T Age at onset Patients 594 25.29 (8.49) 27.38 (9.74) 29.19 (10.47)  0.14 0.00079 0.044
California verbal
learning
Scz 227 11.00 (2.73) 11.94 (2.58) 12.82 (2.59)  0.25 0.00014 0.0078
— rs9636107 G Age at onset Patients 591 29.06 (11.01) 28.07 (9.65) 25.51 (8.76) 0.14 0.00049 0.027
9 rs41396445 A Temporal cortical
area
All 480 41660 (4050) 42480 (4231) 43380 (4511)  0.12 0.00083 0.046
California verbal
learning
Scz 227 12.95 (2.39) 12.40 (2.72) 11.32 (2.61) 0.22 0.00081 0.045
9 rs682245 T Cerebellar volume Scz 106 146700 (13250) 135600 (13020) 132500 (16150) 0.28 0.00074 0.041
9 rs17514242 G Temporal cortical area All 480 41440 (3966) 42490 (4274) 43360 (4458)  0.13 0.00053 0.030
Brain volume All 480 1150000 (121700) 1170000 (141900) 1203000 (134500)  0.12 0.00067 0.038
9 rs12458118 A Cerebellar volume Scz 106 146700 (13250) 135600 (13020) 132500 (16150) 0.28 0.00074 0.041
9 rs9951280 G Cerebellar volume Scz 106 146700 (13250) 135600 (13020) 132500 (16150) 0.28 0.00074 0.041
9 rs10871582 A Temporal cortical area All 480 41520 (3982) 42450 (4279) 43370 (4450)  0.13 0.00056 0.031
Brain volume All 480 1153000 (122400) 1169000 (142200) 1203000 (134200)  0.12 0.00083 0.046
California verbal
learning
Scz 227 13.00 (2.33) 12.42 (2.72) 11.36 (2.62) 0.23 0.00083 0.046
Abbreviations: LD, linkage disequilibrium; N, number; P, uncorrected P-value; s.d., standard deviation; SNP, single nucleotide polymorphism.
aMean and standard deviation in homozygotes for minor allele
bHeterozygotes.
cHomozygotes for major allele.
dStandardized regression coefﬁcient.
eSigniﬁcant P-
values after controlling for multiple testing across independent genotypes and phenotype families. Of note, six remained signiﬁcant after controlling for all the 19
phenotypes.
fCalifornia Verbal Learning test- Second edition (CVLT-II), total learning score (trial A1-5). Scz: Schizophrenia group. Patients: all patients. All: total
sample with patients and controls. Results surviving correction for multiple testing in the linear regression analysis of TCF4 SNPs and phenotypes, correcting for
diagnosis and gender.
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associated with reduced brain volume and cortical area,
47
while mutations cause primary microcephaly.
48
Psychotic disorders are a heterogenous group of diseases
and division into subgroups based on symptomatology might
be desirable. The consistent effect of the TCF4 SNPs of
several sequential haploblocks on negative symptoms in
schizophreniapatientsmightbeapathtodeﬁneasubgroupof
patients with more pronounced negative symptoms as
previously suggested.
49,50 Interestingly, the variants that
affect negative symptoms are situated in the exon-dense
region of the gene in which Pitt–Hopkins syndrome–causing
mutations (exons 9–19) are identiﬁed.
51 Furthermore, we
foundthatone SNP was associated with both anearlier ageat
onset and worse verbal learning. Cognitive decline and early
age at onset are predictors of poor prognosis in schizo-
phrenia.
52 The pattern of clinical symptoms and cognitive
dysfunction resembles what has been regarded as neurode-
velopmental characteristics, and is consistent with an effect of
TCF4onabnormalneurodevelopment.Theconsistentpattern
of effect across different SNPs on independent clinical,
cognitive and brain imaging phenotypes suggests that the
current ﬁndings are not due to chance.
TCF4 mRNA levels were signiﬁcantly higher in the patient
groups compared with controls. Measurements in the blood
allow for larger sample sizes and better standardization of
technical procedures, but it might not reﬂect mRNA levels in
the brain. It has previously been reported that the availability
of an accessible tissue, such as blood, with similar gene
expression to a more inaccessible tissue, such as brain, may
advance research in neuropsychiatric disorders.
53 Sullivan
et al.
53 reported that, on a transcriptome level, whole blood
shares signiﬁcant gene expression similarities with brain
tissue.Thus,eventhoughitwasnotperfectlycorrelated,gene
expression in blood might be a useful surrogate marker for
gene expression in the central nervous system.
53 Our
observation of increased level of TCF4 mRNA in patients
with schizophrenia is consistent with increased cerebellar
expression of TCF4 in schizophrenia patients shown in a
genomic convergence analysis on post-mortem cerebellar
cortices,
54 indicating that in the case of TCF4, blood and brain
expression might correlate. Microarrays of gene expression in
bloodisapracticalmethodtouseinpsychoticpatientsandthe
technique has become increasingly accepted for studying
biomarkers for neuropsychiatric diseases.
55–63 For example,
gene expression in peripheral blood mononuclear cells in
patients with multiple sclerosis was correlated to disease
activity.
64 This is in line with our ﬁnding of a correlation
between mRNA level and severity of positive and negative
symptoms in patients with schizophrenia.
The result of increased TCF4 mRNA in psychotic patients
should be interpreted with caution as an effect on mRNA
levels of prescribed psychotropic medications cannot
be excluded. We did ﬁnd an overall effect of medication on
mRNA level in patients, with the highest level in patients on
antipsychotics or treated with several types of psychotropics,
even though it did not survive correction for multiple testing.
Thus, the observed effect might be a mirror of medication or
reﬂect a more severe form of psychosis in patients on regular
medical treatment. The trend of higher TCF4 mRNA level in
unmedicated patients compared with controls does corro-
borate an effect regardless of medication, though. Another
small-size (41 patients) study observed less TCF4 expression
in blood from patients with higher rates of delusions.
39 TCF4
mRNA level was positively correlated with positive and
negative symptoms in our sample. This is in line with our
ﬁnding of several SNPs associated with negative symptoms,
whichmightreﬂectadifferenceinTCF4expressioninpatients
with high level of positive and negative symptoms and
suggests that TCF4 variants may contribute to more
pronounced symptoms. The reason for the apparent dis-
crepancy between Kurian et al. and our ﬁndings might reﬂect
different assumptions. While they compared TCF4 mRNA
levelinpatientswithschizophreniawithhighlevelofdelusions
and patients with no delusions, our sample is generally in a
more chronic phase of disease. Further, our sample is much
larger and more heterogeneous and includes bipolar disorder
and other psychoses, while they include different ethnicities.
Therefore, before TCF4 mRNA can be used as a biomarker
for psychosis, any putative effect of the level of positive and
Figure 2 A TCF4 linkage disequilibrium map and a Manhattan plot with
negative log P-values (uncorrected) from the exploratory single nucleotide
polymorphism–phenotype analysis. Only phenotypes remaining signiﬁcant after
multiple testing is illustrated. AO, age at onset in total patient sample; BV, brain
volume in total sample; CV, cerebellar volume in schizophrenia sample; CVLT,
California Verbal Learning test in schizophrenia sample; Mbp, mega base pair; NS,
negative symptoms in schizophrenia sample; TCA, temporal cortical area in total
sample.
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needs further investigation.
Two recent studies have found allele-speciﬁc expression of
TCF4 in post-mortem human brains.
65,66 No signiﬁcant
association between mRNA level and the common TCF4
polymorphisms was found in our data after correction for
multipletesting,buttherewerenominalassociations.Thelack
of signiﬁcant support for cis-regulatory effect could be due to
Type II error, as there are many factors that affect expression
levels and may mask the effect. It may also be due to
differences in eQTLs in blood and brain tissues. Given the
observed small differences in transcript levels and the
deleteriousness of hemizygosity for TCF4 observed in Pitt–
Hopkins syndrome, it seems reasonable that evolutionary
constraint on variants that alter expression levels might exist.
Anotheroptionisthatthelocus onlyexertsitsregulatoryeffect
in a developmental context, or is organ speciﬁc. The gene
expression in uteri and postnatal life has recently been
examined, and the brain TCF4 mRNA level is highest in the
early brain development in uteri, decreases in childhood and
stabilizes in early adulthood.
67 Thus, epigenetic factors from
early life may have a continued effect on expression
68 and
together with a decrease in variation explain the lack of
association between GWAS SNPs and TCF4 mRNA level in
adults.
67 It is also possible that none of the current TCF SNPs
tagged the eQTLs.
Taken together, these results support earlier ﬁndings of
TCF4asanimportantgeneinpsychosisetiology,andsuggest
that TCF4 variants may lead to a subgroup of psychosis with
clinical, cognitive and brain structural abnormalities related to
neurodevelopmental mechanisms.
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